Welcome to our dedicated page for SI-BONE SEC filings (Ticker: SIBN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SI-BONE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SI-BONE's regulatory disclosures and financial reporting.
SI-BONE, Inc. filed a current report describing that it has released a press release with preliminary unaudited revenue and cash and equivalents figures for the fourth quarter and full year 2025. These early numbers are meant to give the market an initial view of the company’s recent performance and year-end liquidity before audited results are available.
The company also plans meetings with investors and analysts, supported by a slide presentation. Both the press release and the presentation are included as exhibits and are being furnished, not filed, which means they are not automatically incorporated into other securities law filings.
SIBN received a notice that an affiliated holder plans to sell common stock under Rule 144. The filing covers a proposed sale of 60,000 common shares, to be executed through Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ market. These 60,000 shares were acquired as restricted stock units from the issuer on October 15, 2021.
Recent trading history in the notice shows that The Jeffrey W. Dunn Living Trust has already sold common shares in the past three months, including 20,000 shares for gross proceeds of 386,594.00 on December 8, 2025, 80,000 shares for 1,516,000.00 on November 11, 2025, and 293 shares for 4,337.51 on November 3, 2025. The planned and recent sales are for the account of that trust, which represents that it is not aware of undisclosed material adverse information about the issuer.
SI-BONE, Inc. executive reports tax-related share sale
SI-BONE, Inc. Senior Vice President, Operations & Administration and Chief Legal Officer Michael A. Pisetsky reported selling small amounts of the company’s common stock on January 2, 2026. The sales, executed in three trades at prices of $19.75, $19.6811, and $19.5788 per share, were made to cover tax withholding obligations tied to the vesting of restricted stock units. According to the disclosure, this was a mandated “sell to cover” transaction and not a discretionary trade.
After these sales, Pisetsky beneficially owned 228,436 shares of SI-BONE common stock directly. This amount includes 119,679 shares that are issuable upon settlement of restricted stock units, each unit representing the right to receive one share of common stock.
SI-BONE, Inc. director Jeffrey W. Dunn reported a series of transactions in the company’s common stock. On December 8, 2025, he exercised a stock option for 1,241 shares at an exercise price of $4.32 per share and acquired those shares.
That same day, he sold 1,241 shares of common stock and separately sold another 18,759 shares, both reported with a weighted-average sale price of $19.3297 per share, with individual sale prices ranging from $19.13 to $19.85. The sales were made under a Rule 10b5-1 trading plan dated May 7, 2025. After these transactions, he beneficially owned 10,307 shares directly, including shares issuable on settlement of restricted stock units, and 110,115 shares indirectly through The Jeffrey W. Dunn Living Trust dated May 17, 2012.
SI-BONE, Inc. (SIBN) reported an insider transaction by its SVP, Ops & Adm/Chief Legal Officer. On 11/24/2025, the officer sold 400 shares of common stock at $20 per share, reported with transaction code "S" for a sale. The filing notes that this trade was made under a Rule 10b5-1 trading plan dated June 13, 2025, which is a pre-arranged plan for selling shares.
After this transaction, the reporting person beneficially owned 251,496 shares of SI-BONE common stock. This total includes 125,823 shares issuable upon settlement of restricted stock units, where each unit represents the right to receive one share of common stock.
SI-BONE, Inc. (SIBN) filed a Form 4 reporting stock sales by its Chief Financial Officer, Anshul Maheshwari. The CFO sold 1,200 shares of common stock on 11/21/2025 at a weighted-average price of about $20.0133 per share and an additional 100 shares on 11/25/2025 at $20.00 per share. These sales were made under a pre-arranged Rule 10b5-1 trading plan dated December 13, 2024, which is designed to allow insiders to sell stock according to a set schedule.
Following these transactions, Maheshwari beneficially owns 203,773 shares of SI-BONE common stock. This total includes 143,116 shares issuable upon settlement of restricted stock units, each representing a right to receive one share of common stock.
SI-BONE, Inc. (SIBN) reported an insider transaction by its President, Commercial Ops, Anthony J. Recupero. On 11/17/2025, he sold 1,707 and 2,126 shares of common stock in two transactions at weighted average prices of $17.4232 and $17.4462, respectively. These sales were made to cover tax withholding obligations arising from the vesting of restricted stock units and are described as non-discretionary “sell to cover” trades.
Following these transactions, the reporting person beneficially owned 268,144 shares of SI-BONE common stock, including 133,316 shares issuable upon settlement of restricted stock units, with each unit representing a contingent right to receive one share.
SI-BONE, Inc. (SIBN) reported an insider transaction by its Senior Vice President, Operations & Administration and Chief Legal Officer on 11/17/2025. The executive sold 1,478 and 1,850 shares of common stock in two separate trades, coded as sales.
According to the disclosure, these sales were made solely to cover tax withholding obligations arising from the vesting of restricted stock units under a "sell to cover" arrangement and are described as non-discretionary trades. After the transactions, the reporting person beneficially owned 251,896 shares of common stock, including 125,823 shares issuable upon settlement of restricted stock units, each unit representing a right to receive one share.
SI-BONE, Inc. insider trading report: The Chief Financial Officer of SI-BONE, Inc. (SIBN) reported two sales of common stock on 11/17/2025 totaling 3,460 shares. One sale covered 1,275 shares at a weighted average price of $17.4098, and another covered 2,185 shares at a weighted average price of $17.4369. According to the disclosure, these transactions were "sell to cover" sales required to satisfy tax withholding obligations related to vesting restricted stock units and were not discretionary trades. After these transactions, the reporting person beneficially owned 205,073 shares of common stock, including 143,116 shares issuable upon settlement of restricted stock units.
SI-BONE, Inc. (SIBN) reported insider transactions by Chief Executive Officer and Director Laura A. Francis. On 11/17/2025, she sold several small blocks of common stock, including 2,028 shares at a weighted average price of $17.4401, 2,231 shares at $17.4449, 3,197 shares at $17.4341, and 3,885 shares at $17.3996.
The filing explains that these sales were required to cover tax withholding obligations tied to the vesting of restricted stock units and were executed as "sell to cover" transactions rather than discretionary trades. On 11/18/2025, 5,411 additional shares were sold at a weighted average price of $17.6978 under a Rule 10b5-1 trading plan dated December 13, 2024.
After these transactions, Francis beneficially owned 408,363 shares directly, including 373,980 shares issuable upon settlement of restricted stock units, and 351,319 shares indirectly through a trust.